ZymoGenetics, Inc. (JOBS) Says Merck Serono Discontinues MS Trials
Reuters -- Biotechnology firm Zymogenetics Inc said its licensee, Merck Serono SA, discontinued trials of its experimental drug, atacicept, for the treatment of multiple sclerosis (MS).